Wall Street and Australian equity research analysts covering Healius Limited (ASX: HLS) maintain consensus 12-month price targets clustering around 0.43 Australian Dollars per share, with lower projections sitting near 0.35 Dollars and optimistic estimates reaching up to 0.59 Dollars. These price targets reflect ongoing market evaluations of the company's post-restructuring operational efficiency, corporate cost-saving execution, debt optimization strategies, and the pace of recovery within its core Australian pathology and diagnostic imaging business segments.